Compounds and methods for treatment of influenza
AssigneeSimon Fraser University
InventorsBrian Mario Pinto, Sankar Mohan
Life of this patent
Estimating the term…
Abstract
The present invention provides in part a compound of Formula (I) or a pharmaceutically-acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3; and R2 is selected from the group consisting of H, Me, Et and an amino acid, and methods and uses thereof.
Claims23
A compound of Formula (I) or a pharmaceutically-acceptable salt or stereoisomer thereof:
- wherein
- R1 is selected from the group consisting of a substituted triazole group, a urea group, a thiourea group, an amidine group, and N3;
- and
- R2 is selected from the group consisting of H, Me, Et and an amino acid.
A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically-acceptable salt or stereoisomer thereof:
- wherein
- R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3;
- and
- R2 is selected from the group consisting of H, Me, Et and an amino acid, in combination with a pharmaceutically acceptable carrier.
A method of inhibiting an influenza virus Type A group-1 neuraminidase in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) or prodrug or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3;
- and
- R2 is selected from the group consisting of H, Me, Et and an amino acid.
A method of treating or preventing an influenza virus Type A infection in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or prodrug or pharmaceutically acceptable salt thereof:
- wherein
- R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3;
- and
- R2 is selected from the group consisting of H, Me, Et and an amino acid.
15-17. (canceled)
A method for screening for a selective inhibitor of an influenza virus group-1 neuraminidase, the method comprising:
- a) contacting a first sample with a test compound;
- b) contacting a second sample with a compound of Formula (I)
- wherein
- R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3;
- and
- R2 is selected from the group consisting of H, Me, Et and an amino acid;
- and
- c) determining the level of inhibition of the influenza virus group-1 neuraminidase in the first and second samples,
- wherein the test compound is a selective inhibitor of an influenza virus group-1 neuraminidase if the test compound exhibits the same or greater inhibition of the influenza virus group-1 neuraminidase when compared to the compound of Formula (I).
A method of making a composition for inhibiting an influenza virus Type A group-1 neuraminidase, the method comprising admixing an effective amount of a compound of Formula (I):
- wherein
- R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3;
- and
- R2 is selected from the group consisting of H, Me, Et and an amino acid;
- with a pharmaceutically acceptable carrier.
A compound of Formula (I) or a pharmaceutically-acceptable salt or stereoisomer thereof:
- wherein
- R1 is a guanidine group;
- and
- R2 is selected from the group consisting of Me, Et and an amino acid.
Dependencies are inferred from the claim text.